ライフサイエンスコーパス: abdominal infection

1 one site of infection (eg, pneumonia, intra-abdominal infection).

2 re unit patients requiring surgery for intra-abdominal infection.

3 er injury in a murine model of polymicrobial abdominal infection.

4 rms of age and gender as well as the site of abdominal infection.

5 to induce abscesses in a rat model of intra-abdominal infection.

6 es in patients with known or suspected intra-abdominal infection.

7 id in patients with known or suspected intra-abdominal infection.

8 ) as promising candidates to detect an intra-abdominal infection.

9 openem in the treatment of complicated intra-abdominal infections.

10 useful adjunct in treating hepatic and intra-abdominal infections.

11 ical intensive care unit patients with intra-abdominal infections.

12 lms in the gastrointestinal tract, and intra-abdominal infections.

13 arly in those with early posttransplantation abdominal infections.

14 s: 10 with wound infections and 2 with intra-abdominal infections.

15 vity against pathogens associated with intra-abdominal infections.

16 infants with suspected or complicated intra-abdominal infections.

17 may benefit a subset of patients, those with abdominal infections.

18 d D. vulgaris has been associated with intra-abdominal infections.

19 provides a clear abdominal field for imaging abdominal infections.

20 ilastatin for treatment of complicated intra-abdominal infections.

21 eriority of short-duration therapy for intra-abdominal infections.

22 ile leakage (4.5% vs 3.1%, P = 0.686), intra-abdominal infections (12.1% vs 10.2%, P = 0.800), and mo

23 ral line-associated), non-C. difficile intra-abdominal infections (14.5%), urinary infections (7.3%,

24 most common interventions were performed for abdominal infection (31.7%; RR mortality = 2.9; 95% CI =

25 lated from human infections, including intra-abdominal infections, abscesses, and bloodstream infecti

26 e days 2, 3, 4, and/or 5 as markers of intra-abdominal infection after elective colorectal surgery.

27 ng the risk of increased postoperative intra-abdominal infections after laparoscopic appendectomy, th

28 infections without any prior surgery, 7 had abdominal infections after surgery, 4 had perianal absce

29 , 30-day readmission rates, ileus, and intra-abdominal infection (all P's > .05).

30 12 for urinary tract infection, 83 for intra-abdominal infection and 45 for bloodstream infection.

31 reinsertion of nasogastric tube), and intra-abdominal infection and association between colorectal c

32 PN was specifically associated with abdominal infection and catheter infection.

33 nfection assays using animal models of intra-abdominal infection and intestinal colonization.

34 ker for the detection of postoperative intra-abdominal infection and the appropriate moment to measur

35 fter bariatric surgery whereas that of intra-abdominal infection and UTI increased.

36 tcome in community-acquired pneumonia, intra-abdominal infections and bloodstream infections, respect

37 ions for example between SNPs identified for abdominal infections and CRP, rheumatoid arthritis, and

38 PPP1R14A showed strong colocalization with abdominal infections and gene expression in sigmoid and

39 ons by logistic regression analysis, and for abdominal infections and pneumonia using matched control

40 After matching patients with abdominal infections and pneumonia with BSI to patients

41 piratory, skin and/or soft tissue, and intra-abdominal infections and were prescribed antimicrobials

42 act infection and ten with complicated intra-abdominal infection) and 148 assigned to best available

43 steoarticular infection, postoperative intra-abdominal infection, and catheter-related bloodstream in

44 nvasive disease, such as endocarditis, intra-abdominal infection, and shock.

45 inary tract infections, 13 (3.8%) with intra-abdominal infections, and 11 (3.2%) with skin and soft-t

46 Twenty-four-hour transfusions, abdominal infections, and hospital length of stay were a

47 aneurysm formation, anastomotic leaks, intra-abdominal infections, and, al. though rare, AVF.

48 0- to 12-month postsurgery period for intra-abdominal infection (aOR, 2.09 [95% CI, 1.78-2.46]) and

49 emergency gastrointestinal surgery for intra-abdominal infection are at risk of invasive candidiasis

50 Intra-abdominal infections are common in young infants and lea

51 Intra-abdominal infections are frequent and life-threatening c

52 Intra-abdominal infections are one of the most common infectio

53 han procalcitonin for the detection of intra-abdominal infection (areas under the ROC curve: 0.775 vs

54 In clinical trials of complicated intra-abdominal infections, assessment of adequacy of the init

55 fference in time to first infection or first abdominal infection between groups.

56 atory cytokine production during acute intra-abdominal infection caused by cecal ligation and punctur

57 urinary tract infection or complicated intra-abdominal infection caused by ceftazidime-resistant Ente

58 ry tract infection (cUTI), complicated intra-abdominal infection (cIAI), community-acquired bacterial

59 registrational trials for complicated intra-abdominal infection (cIAI).

60 al trials in patients with complicated intra-abdominal infections (cIAI).

61 ce among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of

62 hospitalized patients with complicated intra-abdominal infections (cIAIs).

63 ncy (EMA) for treatment of complicated intra-abdominal infections (cIAIs).

64 onsensus Criteria) due to pneumonia or intra-abdominal infection (cohorts 1-3, n=2534 patients).

65 Intra-abdominal infection decreased from 7.4% to 2.5% (P = .24

66 r operative management in terms of decreased abdominal infections, decreased transfusions, and decrea

67 Recurrent intra-abdominal infection developed in 15 patients, but only 1

68 urinary tract infection or complicated intra-abdominal infection due to ceftazidime-resistant Gram-ne

69 hest during natural disaster missions, intra-abdominal infections during hospital support missions, a

70 fections, 15 (29.4%) had postoperative intra-abdominal infections, eight (15.7%) had postoperative sk

71 is rodent model of antibiotic-treated, intra-abdominal infection features key characteristics of clin

72 in 1066 men and women with complicated intra-abdominal infections from 2 identical, randomized, doubl

73 ays of age with suspected or confirmed intra-abdominal infections hospitalized in 24 neonatal intensi

74 rbidity after liver transplantation is intra-abdominal infection (IAI) about which there are limited

75 using a murine model of polymicrobial intra-abdominal infection (IAI) demonstrates that synergistic

76 Candida albicans-Staphylococcus aureus intra-abdominal infection (IAI) results in 100% mortality by 4

77 Polymicrobial intra-abdominal infections (IAI) are clinically prevalent and

78 Intra-abdominal infections (IAIs) after elective colorectal su

79 l trials of antibiotics in complicated intra-abdominal infections identified through systematic revie

80 ch to treat septicemia associated with intra-abdominal infection in a murine model by delicately bala

81 ase (NDM)-5-producing Escherichia coli intra-abdominal infection in whom resistance to cefiderocol ev

82 robiological evaluation of complicated intra-abdominal infections in adults, children, and pregnant p

83 robiological evaluation of complicated intra-abdominal infections in adults, children, and pregnant p

84 robiological evaluation of complicated intra-abdominal infections in adults, children, and pregnant p

85 iagnosis and management of complicated intra-abdominal infections in adults, children, and pregnant p

86 hreatening disease via bloodstream and intra-abdominal infections in immunocompromised and transplant

87 These data suggest that severe polymicrobial abdominal infection induces prothrombotic FXI activation

88 ndromes, including urinary tract infections, abdominal infections, nosocomial pneumonia, neonatal men

89 omplications such as graft thrombosis, intra-abdominal infection, or abscess were reported.

90 fection (SSTI), respiratory infection, intra-abdominal infection, or urinary tract infection (UTI).

91 ic therapy for patients with localized intra-abdominal infections ranging from mild to moderate sever

92 ies of bacterial and viral infections (e.g., abdominal infections, respiratory infections, and sepsis

93 Intra-abdominal infections result in substantial morbidity, mo

94 Staphylococcus aureus-Candida albicans intra-abdominal infection results in approximately 60% mortali

95 short-course antimicrobial therapy for intra-abdominal infection (STOP-IT), and results suggest globa

96 ntigen-induced shock and polymicrobial intra-abdominal infection, supporting its potential use in cli

97 Despite the prevalence of intra-abdominal infections, urinary tract infections, and skin

98 5 anti-infective agents in complicated intra-abdominal infections used a source control review proces

99 The incidence of intra-abdominal infection was 11.8%, with 24.6% of patients pr

100 Intra-abdominal infection was the most common source of infect

101 Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, dou

102 ients with sepsis due to pneumonia and intra-abdominal infection were combined.

103 nor (76%), whereas most operations for intra-abdominal infections were major (98%).

104 Retransplantation and intra-abdominal infections were major risk factors.

105 ract infection and 11 with complicated intra-abdominal infection) were analysed for the primary outco

106 inary tract infections and complicated intra-abdominal infections (when used with metronidazole).

107 ) mice were generated and subjected to intra-abdominal infection with Klebsiella pneumoniae, which re

108 wo patients had bacteremic infections, 4 had abdominal infections without any prior surgery, 7 had ab

109 complicated urinary tract infections, intra-abdominal infections), yet these designs may not be opti